Mineralys Therapeutics
Mineralys Therapeutics develops oral aldosterone synthase inhibitors for hypertension, chronic kidney disease, and obstructive sleep apnea.
10-KSep 25Latest SEC filing
Aug 11Latest story
August 2026
Sign inSign inMineralys Therapeutics develops oral aldosterone synthase inhibitors for hypertension, chronic kidney disease, and obstructive sleep apnea.